AR060471A1 - Organismos clostridium recombinantes atenuados y vacuna - Google Patents

Organismos clostridium recombinantes atenuados y vacuna

Info

Publication number
AR060471A1
AR060471A1 ARP070101608A ARP070101608A AR060471A1 AR 060471 A1 AR060471 A1 AR 060471A1 AR P070101608 A ARP070101608 A AR P070101608A AR P070101608 A ARP070101608 A AR P070101608A AR 060471 A1 AR060471 A1 AR 060471A1
Authority
AR
Argentina
Prior art keywords
organisms
recombinants
vaccine
damaged
attenuated
Prior art date
Application number
ARP070101608A
Other languages
English (en)
Original Assignee
Schering Plough Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Plough Ltd filed Critical Schering Plough Ltd
Publication of AR060471A1 publication Critical patent/AR060471A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Fodder In General (AREA)
  • Feed For Specific Animals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Organismos Clostridium perfringens atenuados, que expresan una toxina alfa sustancialmente no toxica. La toxina alfa expresada es una muteína de delecion a la que, en relacion con la toxina alfa de la toxina alfa madura de la cepa 13 de Clostridium perfringens, le faltan por lo menos 9 residuos de aminoácidos consecutivos, que incluyen His68. Además organismos atenuados que codifican las muteínas, y también, el uso de dichos organismos atenuados como vacunas.
ARP070101608A 2006-04-17 2007-04-16 Organismos clostridium recombinantes atenuados y vacuna AR060471A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US79255306P 2006-04-17 2006-04-17

Publications (1)

Publication Number Publication Date
AR060471A1 true AR060471A1 (es) 2008-06-18

Family

ID=38625523

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP070101608A AR060471A1 (es) 2006-04-17 2007-04-16 Organismos clostridium recombinantes atenuados y vacuna
ARP110100176A AR079941A2 (es) 2006-04-17 2011-01-19 Organismos clostridium atenuados recombinados y vacuna

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP110100176A AR079941A2 (es) 2006-04-17 2011-01-19 Organismos clostridium atenuados recombinados y vacuna

Country Status (24)

Country Link
US (3) US7732187B2 (es)
EP (2) EP2368571A1 (es)
JP (2) JP5551933B2 (es)
KR (1) KR20080110908A (es)
CN (1) CN101489584B (es)
AR (2) AR060471A1 (es)
AU (1) AU2007240949B2 (es)
BR (1) BRPI0711572A2 (es)
CA (1) CA2649426C (es)
CO (1) CO6140037A2 (es)
EC (1) ECSP088827A (es)
ES (1) ES2401810T3 (es)
HK (1) HK1125315A1 (es)
IL (1) IL194714A (es)
MX (1) MX2008013451A (es)
NO (1) NO20084810L (es)
NZ (1) NZ571970A (es)
PE (1) PE20080167A1 (es)
PL (1) PL2007420T3 (es)
RU (2) RU2593945C2 (es)
TW (1) TWI338045B (es)
UA (2) UA109105C2 (es)
WO (1) WO2007123850A2 (es)
ZA (1) ZA200808872B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070077256A1 (en) 1999-11-19 2007-04-05 Los Angeles Biomedical Research Institute Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis and other infectious agents
US20060083750A1 (en) * 1999-11-19 2006-04-20 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis
MX343525B (es) * 2008-04-29 2016-11-09 Immunexcite Inc Composiciones inmunomoduladoras y metodos de uso de las mismas.
AU2011299285B2 (en) * 2010-09-10 2017-01-05 Ntcd, Llc Environmental Clostridial bacteriotherapy and related formulations and methods of manufacture and use
EP2734229B1 (en) 2011-07-22 2019-01-02 Novadigm Therapeutics, Inc. Methods and copositions for vaccinating against staphylococcus aureus
EP2820044A1 (en) * 2012-03-02 2015-01-07 Regeneron Pharmaceuticals, Inc. Human antibodies to clostridium difficile toxins
BR112015008775A2 (pt) 2012-10-26 2017-07-04 Intervet Int Bv sorotipo c1 do sorogrupo de salmonella enterica, uso de um sorotipo c1 do sorogrupo de salmonella enterica, e, vacina para administração a aves
CA2906771A1 (en) 2013-03-15 2014-09-18 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Compositions and methods for treating fungal and bacterial pathogens
WO2017155949A1 (en) 2016-03-09 2017-09-14 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Methods and kits for use in preventing and treating vulvovaginal candidiasis
CN109602898B (zh) * 2018-12-28 2022-02-22 江苏省农业科学院 一种产气荚膜梭菌α毒素基因工程疫苗及其制备方法
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
CN114621963A (zh) * 2022-03-11 2022-06-14 牧原食品股份有限公司 一种猪魏氏梭菌a型的亚单位疫苗及其制备

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1483042A (en) * 1974-07-29 1977-08-17 Lapointe J Anti-tumour product of bacterial origin
SU627611A1 (ru) * 1977-09-30 1980-02-05 В.П. Землякова Вакцинный препарат в.п. земл ковой против клостридиозов животных и птиц
GB9115332D0 (en) * 1991-07-16 1991-08-28 Connaught Lab Manipulation of gene copy number in bordetella
MX9302964A (es) * 1992-05-20 1995-01-31 Secr Defence Vacunas de clostridium perfringens.
GB9605222D0 (en) 1996-03-12 1996-05-15 Secr Defence Clostridium perfringens epsilon toxin vaccines
ATE346931T1 (de) * 1997-06-20 2006-12-15 Intervet Int Bv Clostridium perfringens impfstoff
RU2129441C1 (ru) * 1997-12-10 1999-04-27 Пирожков Михаил Константинович Вакцина, ассоциированная против анаэробной энтеротоксемии и эшерихиоза поросят
US6399074B1 (en) * 1998-07-24 2002-06-04 Megan Health, Inc. Live attenuated salmonella vaccines to control avian pathogens
AUPQ899700A0 (en) * 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
KR20050098837A (ko) * 2002-12-09 2005-10-12 유니버시티 오브 조지아 리서치 파운데이션 인코퍼레이티드 구포자충 백신 및 이를 사용하고 제조하는 방법
BRPI0416376A (pt) * 2003-11-10 2007-03-06 Uab Research Foundation composições para a redução da colonização bacteriana e da invasão do snc e métodos de uso destes
MY149604A (en) * 2005-04-18 2013-09-13 Schering Plough Ltd C.perfringens alpha toxoid vaccine

Also Published As

Publication number Publication date
US20100166800A1 (en) 2010-07-01
CA2649426C (en) 2014-04-01
EP2007420A2 (en) 2008-12-31
UA109105C2 (uk) 2015-07-27
EP2368571A1 (en) 2011-09-28
RU2011147308A (ru) 2013-05-27
IL194714A0 (en) 2011-08-01
AU2007240949B2 (en) 2013-03-14
UA95951C2 (en) 2011-09-26
CN101489584B (zh) 2013-05-01
NZ571970A (en) 2012-02-24
RU2593945C2 (ru) 2016-08-10
AR079941A2 (es) 2012-02-29
WO2007123850A2 (en) 2007-11-01
IL194714A (en) 2015-03-31
CA2649426A1 (en) 2007-11-01
EP2007420B1 (en) 2013-03-06
CO6140037A2 (es) 2010-03-19
ECSP088827A (es) 2008-11-27
US20070286874A1 (en) 2007-12-13
TW200801182A (en) 2008-01-01
WO2007123850A3 (en) 2008-03-06
ZA200808872B (en) 2009-11-25
JP2009533071A (ja) 2009-09-17
JP2013255518A (ja) 2013-12-26
HK1125315A1 (en) 2009-08-07
NO20084810L (no) 2009-01-16
US7732187B2 (en) 2010-06-08
ES2401810T3 (es) 2013-04-24
JP5551933B2 (ja) 2014-07-16
TWI338045B (en) 2011-03-01
CN101489584A (zh) 2009-07-22
MX2008013451A (es) 2008-10-30
KR20080110908A (ko) 2008-12-19
AU2007240949A1 (en) 2007-11-01
PL2007420T3 (pl) 2013-08-30
RU2008144913A (ru) 2010-05-27
US20110008389A1 (en) 2011-01-13
US7807456B2 (en) 2010-10-05
BRPI0711572A2 (pt) 2011-11-16
PE20080167A1 (es) 2008-03-10
RU2445364C2 (ru) 2012-03-20
US7972604B2 (en) 2011-07-05

Similar Documents

Publication Publication Date Title
AR060471A1 (es) Organismos clostridium recombinantes atenuados y vacuna
PE20161551A1 (es) Vacuna de pcsk9
CL2009000091A1 (es) Enzima n-acetilgalactosamina-6-sulfatasa (galns) humana recombinante; usos de la enzima galns contra mucopolisacaridosis tipo iv o sindrome de morquio a o deficiencias de multiples sulfatasas.
ATE552846T1 (de) Verbesserter grippeimpfstoff
UA94717C2 (ru) Модифицированный вирус гриппа, предназначенный для мониторинга и повышения эффективности вакцины
AR074311A1 (es) Variantes de subtilisina aislada de bacillus, con actividad proteolitica
AR061930A1 (es) Mimeticuerpos de glp-1 humanos, composiciones, metodos y usos
AR060565A1 (es) Vacuna para la gripe aviaria y metodos de uso
AR040204A1 (es) Composicion de vacuna meningococica multivalente
EP1907014A4 (en) CHONDROGENIC COMPOSITIONS AND METHODS OF USE
RS53505B1 (en) OXYTOMODULIN PEPTIDE ANALOG
WO2005021707A3 (en) Severe acute respiratory syndrome dna vaccine compositions and methods of use
WO2008156778A3 (en) Influenza m2 protein mutant viruses as live influenza attenuated vaccines
MX2011006846A (es) Virus de fiebre porcina clasico recombinante (csfv) comprendiendo una proteina e2 modificada y metodos para generar dicho csfv.
ECSP11010975A (es) Método de uso de una cepa de bacillus subtilis para mejorar la salud de animales
PE20100056A1 (es) Analogos de glucagon como agonistas gip
AR052030A1 (es) Nueva composicion para facilitar el parto humano
SG178797A1 (en) Oligosaccharide chain added glp-1 peptide
ATE547118T1 (de) Rekombinanter koi-herpesvirus (khv) oder cyprinid-herpesvirus 3 (cyhv-3) und impfstoff zur prävention einer von khv/cyhv-3 bei cyprinus carpio carpio oder cyprinus carpio koi verursachten erkrankung
ES2530670T3 (es) Anticuerpo anti-FGF23 y composición farmacéutica que comprende el mismo
PE20121528A1 (es) Metodos para administrar agentes hipoglucemiantes de larga duracion
AR094725A1 (es) Parvovirus 5a porcino, métodos de uso y vacuna
NZ592911A (en) Leukolectins and uses thereof
NZ594268A (en) Grass peptides for vaccine
BRPI0516314A (pt) uso de hiv inteiro e método de tratamento de um indivìduo cronicamente infectado com hiv

Legal Events

Date Code Title Description
FG Grant, registration